Discover 1 curated intelligence briefings related to this specific topic.
While clinical trials show 90% immune response rates for pancreatic cancer vaccines, the actual deployment of genomic medicine is being throttled not by science, but by the inability of health plans to accurately price and pay for individualized care.
